Introduction {#Sec1}
============

Schizophrenia is a debilitating disorder characterized by positive symptoms, such as delusions and hallucinations, and negative symptoms, such as a flat affect, alogia, and anhedonia, as well as deficits in cognition and reward modulation^[@CR1]--[@CR3]^. Some of the psychopathology of schizophrenia is characterized by dopaminergic and glutamatergic dysregulation, increased stress vulnerability via hypothalamic--pituitary--adrenal (HPA) axis dysregulation, cognitive deficits, which include alterations in the cholinergic system, and deficits in reward modulation^[@CR2]--[@CR7]^.

The nociceptin receptor (NOPr) is a G protein-coupled receptor identified in 1994, and was initially classified as a member of the opioid receptor family based on structural homology to the opioid receptors^[@CR8]^. However, it was later reclassified as a non-opioid member of the opioid system, because endogenous ligands for other opioid receptors, such as the mu, kappa, and delta receptors, showed little affinity for it. The endogenous peptide, now known as nociceptin/orphanin FQ (N/OFQ), was identified in 1995, and is a heptadecapeptide with pro-nociceptive properties^[@CR9],[@CR10]^. In vitro receptor autoradiography in rats and post-mortem studies in humans have shown NOPr to be widely distributed, with greater density in cortical regions and the human striatum^[@CR11],[@CR12]^. Positron emission tomography (PET) studies using the ligand \[^11^C\]NOP-1A have corroborated these findings in vivo, with high concentrations of NOPr observed in the cerebral cortex and the striatum^[@CR13]^. Given this widespread expression, it is well positioned to interact with multiple receptor systems in the brain and be involved in several functions.

In investigating the NOPr system, the majority of the literature is a result of preclinical work. This highlights a need for more research into this system as it could have potential in elucidating and treating psychiatric disorders. With regard to schizophrenia, the NOPr system may indeed have an impact given its involvement in important neurotransmitter systems and symptom clusters particularly relevant for the disorder.

Methods {#Sec2}
=======

The goal of this systematic review is to describe the role of the NOPr system in specific systems and symptoms that are relevant to schizophrenia. Thus, in this review we searched for the involvement of the NOPr system in each of the aforementioned domains relevant to schizophrenia. A search was conducted on the MEDLINE database for all research articles from 1994 onward using the Boolean string "(nociceptin receptor OR orl1 OR N/OFQ OR nociceptin/orphanin FQ OR orphanin FQ) AND (stress OR hypothalamic--pituitary--adrenal OR HPA OR immune system OR immune cells OR cytokines OR reward OR place preference OR cognition OR learning OR memory OR acetylcholine OR potentiation OR dopamine OR glutamate OR behavior OR locomotor OR schizophrenia OR psychosis OR post mortem OR microdialysis)". The most recent search was conducted on October 3rd 2017. The abstracts for each of the articles in the search results were then screened using the following inclusion criteria: (a) studies investigating NOPr system involvement in cognition, stress, reward, cholinergic modulation, dopamine modulation, or glutamate modulation, and (b) that could be related to the symptoms underlying schizophrenia. Exclusion criteria were as follows: (a) studies that investigated novel ligands for NOPr investigation; (b) studies investigating pain or pain mechanisms; (c) studies that were unrelated to any of the four domains mentioned above or that could not be related to schizophrenia symptomatology; and (e) general review articles. The flowchart for this process is depicted in Fig. [1](#Fig1){ref-type="fig"}. We also want to note that, while there is evidence for NOPr system involvement in serotonin, β-endorphin, and norepinephrine signaling, these were excluded from this review in favor of focus on well-supported systems in psychosis.Fig. 1Flowchart of the searching process for articles

Results {#Sec3}
=======

A total of 743 articles were obtained through the search, which were then screened. Following screening of abstracts, 123 articles were identified as potentially relevant to this review, and of these, 119 were included in this systematic review. Our discussion will thus focus on results from four areas of research relevant to psychosis: (1) NOPr system involvement in dopamine and glutamate transmission; (2) NOPr system involvement in stress and HPA modulation; (3) NOPr system involvement in cognition; and (4) NOPr system involvement in reward modulation.

Involvement of the NOPr system in dopamine transmission {#Sec4}
-------------------------------------------------------

A common pathology in schizophrenia is characterized by the dopamine hypothesis, which suggests an increased striatal dopamine transmission in these individuals^[@CR4]^. Evidence suggests that the NOPr system could play a role. An initial study by Norton et al. revealed the presence of NOPr on cell bodies of dopamine neurons in the midbrain and a co-localization of NOP mRNA with tyrosine hydroxylase (TH) neurons, with mRNA also present on tegmental and nigral dopaminergic neurons^[@CR14]^. This localization of NOP mRNA was later confirmed with an experiment using 6-hydroxydopamine lesions in rats, in which a large loss of TH neurons led to a reduction of N/OFQ and NOPr mRNA in the caudate putamen^[@CR15]^. TH is an enzyme involved in the synthesis of the dopamine precursor L-DOPA, which plays a critical role in dopamine synthesis^[@CR16]^. Olianas et al. furthered these findings by demonstrating an inhibitory effect of N/OFQ on TH phosphorylation, which inhibited dopamine transmission presynaptically^[@CR17]^. They also observed a selective post-synaptic downregulation of dopamine D1 receptor signaling in the nucleus accumbens and striatum after N/OFQ administration. An involvement with dopamine D2 receptor signaling is also noted given that administration of a D2 antagonist prevented the improvements in motor performance with NOPr antagonists^[@CR18]^. In the same study, genetic knockout of the D2 receptor erased the motor facilitating effect of a low dose of N/OFQ, indicating that the NOPr system could also exert effects on dopamine transmission through this receptor, potentially via a presynaptic mechanism as suggested by the authors.

Early research showed intracerebroventricular (ICV) administration of N/OFQ to induce a reduction in locomotor activity in mice at comparatively high doses (1--10 nmol), which is a finding that was later corroborated in rats and with additional studies in mice at the same doses^[@CR10],[@CR19]--[@CR21]^. These effects were then theorized to occur indirectly via their actions on dopaminergic neurons. Indeed, N/OFQ inhibits dopamine transmission in striatal brain slices^[@CR22]^. In another study, injection of N/OFQ resulted in regulation of motor performance in rats, with injection of a NOPr antagonist producing the opposite effect and leading to an increase in excitability of the motor cortex^[@CR23]^. This motor behavior may be regulated by effects on cortical afferents produced by subcortical NOPr. Liu et al. demonstrated, in vitro, an inhibitory effect of a low dose of N/OFQ on the dopamine transporter, which inhibits dopaminergic activity^[@CR24]^. They theorized this to be a potential mechanism for the decrease in locomotor activity seen in earlier studies. However, given the presence of NOPr on dopamine neurons and NOP mRNA in TH neurons, and the additional evidence of a decrease in motor cortex excitability, the NOPr system could also inhibit dopamine transmission via a direct impact on dopamine synthesis.

Di Giannuario et al. reported a reduction in morphine-induced dopamine release induced by treatment with N/OFQ in vivo^[@CR25]^. On a similar stream, antagonism of NOPr has also been repeatedly shown to enhance dopamine transmission^[@CR26],[@CR27]^. Marti et al. supported the in vitro evidence by demonstrating an inhibitory effect of N/OFQ administration on dopamine transmission in the striatum in vivo^[@CR26]^. Marti et al. demonstrated these effects in a Parkinsonian model by showing improvements in Parkinsonian symptomatology following antagonism of NOPr in the nigrostriatal pathway, furthering the notion of an inhibitory effect of NOPr on dopamine transmission^[@CR27]^. This evidence is further supported by additional preclinical investigations using Parkinsonian models^[@CR28]--[@CR30]^. Viaro et al^[@CR26]^. demonstrated an attenuation of Parkinsonism in MPTP-treated mice with a NOPr antagonist, and a synergistic effect when this was employed with L-DOPA, indicating that the NOPr system was exerting its effects via dopamine transmission (also supported by Marti et al.^[@CR29]^)^[@CR28],[@CR31]^.

More recently, neuroprotective effects of NOPr downregulation on dopamine neurons were demonstrated by Arcuri et al.^[@CR32]^. They observed a significantly greater (50%) amount of nigral dopamine neurons spared in mice following acute administration of MPTP. These findings led the authors to conclude that NOP-N/OFQ signaling contributes to dopamine neuron loss in Parkinson's, speculated to be due to glutamate-mediated excitotoxic mechanisms, and provide support to previous findings^[@CR33],[@CR34]^. Although the aforementioned evidence conveys a definite impact of the NOPr system on dopamine transmission, the exact mechanism by which this occurs is still unclear.

Ces et al.^[@CR33]^ investigated NOPr signaling with pre-pulse inhibition (PPI), a validated model for schizophrenia and demonstrated an impairment of visual PPI with a NOPr agonist^[@CR35],[@CR36]^. Authors also found that co-administration of haloperidol and the NOPr agonist attenuated PPI deficits, leading them to conclude that there is a functional cooperation between N/OFQ and dopamine. This evidence furthers the notion of the possibility of a role for NOPr signaling in schizophrenia.

Involvement of the NOPr system in glutamate transmission {#Sec5}
--------------------------------------------------------

The glutamate hypothesis of schizophrenia is also well accepted, demonstrating hypofunction of the *N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAr), leading to a downregulation of glutamate^[@CR5]^. In light of the significant impact of NOPr signaling on neurotransmission, glutamate transmission has also been studied. Nicol et al. showed decreased K^+^-evoked glutamate release in rat cerebrocortical, cerebellar, and brainstem slices in response to N/OFQ administration (see also Meis and Pape)^[@CR37]--[@CR39]^. Gompf et al. also showed N/OFQ to inhibit glutamate release in the retinohypothalamic tract and suprachiasmatic nucleus, and accorded this to be the result of presynaptic mechanisms by reducing Ca^2+^ (presynaptic release machinery)^[@CR40]^. This was corroborated more recently by Kallupi et al., who demonstrated N/OFQ decreased glutamate release in the rat central amygdala^[@CR41]^. Conversely, Marti et al. reported decreased glutamate release after NOPr antagonism in rats^[@CR27]^. The difference in evidence may be reconciled by the consideration of the effects of NOPr on GABAergic signaling^[@CR42]--[@CR47]^.

Marti et al. reported a stimulatory effect of N/OFQ on nigral glutamate in vivo, and proposed this to be mediated via either dopaminergic or GABAergic mechanisms; this is because a GABA~A~ receptor antagonist was found to counter the effects of N/OFQ^[@CR48]^. The GABAergic system is involved in the pathophysiology of psychosis, as has been demonstrated by post-mortem studies showing abnormal GABAergic interneurons (see review: Taylor and Tso and also Wassef et al.)^[@CR47],[@CR49]^. Gavioli et al. showed NOPr signaling to be involved in anxiety through the GABA~A~ receptor, indicating through in vivo data the existence of effects of the NOPr system on GABAergic signaling^[@CR43]^. Collectively, the data indicate a role of NOPr signaling in glutamate, as well as GABA transmission, with more evidence required to define the effects and exact mechanisms involved. A summary of these and additional findings is provided in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1NOPr in dopamine transmissionExperimentAnimalFindingsReferenceN/OFQ ICV/haloperidolMice↑ In locomotor activity (doses as low as 10 ng)/effect reversed with haloperidolFlorin et al.^[@CR107]^N/OFQ ICVMice and rats↓ In locomotor activityReinscheid et al.^[@CR10]^; Noble and Roques^[@CR20]^; Devine et al.^[@CR19],[@CR108]^; Rizzi et al.^[@CR21]^; Narayanan et al.^[@CR109]^; Chesnokova et al.^[@CR110]^NOPr knockoutRats (crossed)↑ Locomotor activityRizzi et al.^[@CR111]^N/OFQ ICV into SNr/UFP-101Male Sprague-Dawley rats↓ Motor activity/↑ motor activity with UFP-101Marti et al.^[@CR23]^D2r knockoutMice↓ Motor facilitation by NOPr antagonistsViaro et al.^[@CR18]^N/OFQSprague-Dawley rats↓ DAT activity/↓ GABA uptakeLiu et al.^[@CR24]^Dual in situ hybridization/6-OHDAMale Sprague-Dawley rats/autoradiographyNOPr presence on DA neurons/NOP mRNA in TH neuronsNorton et al.^[@CR14]^; Maidment et al.^[@CR112]^N/OFQGuinea pig and mouse striatal slices/rats/in vitro/primary culture/mice↓ DA release (and cocaine-induced DA release)Flau et al.^[@CR22]^; Di Giannuario et al.^[@CR25]^; Murphy et al.^[@CR113]^; Zheng et al.^[@CR114]^; Murphy and Maidment^[@CR46]^; Murphy et al.^[@CR115]^; Lutfy et al.^[@CR116]^UFP-101Mice (wild type)No effect on mesolimbic DAKoizumi et al.^[@CR117]^Compound BMice↑ DA releaseKoizumi et al.^[@CR118]^N/OFQ microdialysisMale Wistar rats↑ DA releaseKonya et al.^[@CR119]^N/OFQ perfused into SNrMale Sprague-Dawley rats↓ DA transmission in striatumMarti et al.^[@CR26]^UFP-101Male Sprague-Dawley rats↓ Haloperidol-induced akinesiaMarti et al.^[@CR120]^N/OFQ after 6-OHDA and L-DOPAMale Sprague-Dawley rats↓ L-DOPA-induced dyskinesia (with N/OFQ)Marti et al.^[@CR121]^6-OHDA or MPTP/J-113397/UFP-101/Compound 24Male Sprague-Dawley rats/mice↓ Parkinsonian symptomsMarti et al.^[@CR27]^; Viaro et al.^[@CR29]^; Volta et al.^[@CR30]^6-OHDA / Trap-101/L-dopaSprague-Dawley rats/mice↓ Parkinsonian symptomsMarti et al.^[@CR28]^; Viaro et al.^[@CR31]^N/OFQMale Sprague-Dawley rats↓ TH phosphorylationOlianas et al.^[@CR17]^6-OHDAMale Sprague-Dawley rats↓ N/OFQ, NOPr mRNA in caudate putamenDi Benedetto et al.^[@CR15]^CSF measurements in PD patientsN/A↑ N/OFQ in striatum and substantia nigraMarti et al.^[@CR122]^Ro64-6198Mice↓ Visual PPICes et al.^[@CR35]^MPTPMice↑ Nigral N/OFQ mRNAGouty et al.^[@CR123]^NOPr or N/OFQ knockout/MPTP/methamphetamineMice↑ Sparing of nigral DA neurons (and striatal)Brown et al.^[@CR33]^; Arcuri et al.^[@CR32]^; Sakoori and Murphy^[@CR34]^*ICV* intracerebroventricular injection, *6-OHDA* 6-hydroxydopamine lesions, *J-113397* NOPr antagonist, *UFP-101* NOPr antagonist with partial agonist properties,*MPT*P 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, *Trap-101* NOPr antagonist, *compound 24 and compound B* NOPr antagonists, *Ro64-6198* NOPr agonist, *DAT* dopamine transporter, *TH* tyrosine hydroxylase, *DA* dopamine, *PPI* prepulse inhibition, *D2r* dopamine D2 receptor subtype, *SNr* substantia nigra pars reticulataTable 2NOPr in glutamate transmissionExperimentAnimalFindingsReferenceN/OFQFemale Wistar rats↓ K^+^-evoked glutamate release in cerebrocortical, cerebellar, and brainstem slicesNicol et al.^[@CR37],[@CR38]^N/OFQLong Evans rats↓ Non-NMDA EPSCMeis and Pape^[@CR39]^NOPr knockoutMice↑ NMDAr functionMamiya et al.^[@CR124]^J-113397 intraperitoneallyMice↓ glutamate releaseMabrouk et al.^[@CR42]^; Marti et al.^[@CR45]^N/OFQ microdialysis/ NOPr antagonistMale Sprague-Dawley rats↑ Nigral glutamate release (countered by antagonist)Marti et al.^[@CR48]^UFP-101Male Sprague-Dawley rats↓ Nigral glutamate release (normalized)Marti et al.^[@CR120]^N/OFQMale Sprague-Dawley rats↓ Glutamate-mediated EPSCGompf et al.^[@CR40]^J-113397/UFP-101Male Sprague-Dawley rats↓ Glutamate releaseMarti et al.^[@CR27]^N/OFQMale Wistar rats↓ Glutamatergic receptor-mediated EPSPsKallupi et al.^[@CR41]^*EPSC/EPSP* excitatory post-synaptic current/potential, *NOPr antagonist* \[Nphe^1^\]nociceptin/orphanin FQ(1--13)NH~2~

Together, the evidence of NOPr involvement in dopamine and glutamate signaling, given the localization patterns and modulatory roles, suggests considerable potential for NOPr signaling in the pathophysiology of schizophrenia.

Involvement of the NOPr system in the HPA axis {#Sec6}
----------------------------------------------

Patients with schizophrenia present with an increased vulnerability to stress, which is thought to be a result of HPA axis dysregulation^[@CR6]^. The NOPr system may be a critical mediator in the stress response via the HPA axis through its effects on adrenocorticotropic hormone and corticosterone. The collective findings are summarized in Table [3](#Tab3){ref-type="table"}. N/OFQ increased corticosterone and adrenocorticotropic hormone in non-stressed rats and in mildly stressed rats, indicating its ability to activate the HPA axis^[@CR50]^. In a similar manner, stress decreased N/OFQ content in the basal forebrain^[@CR51]^. Leggett et al. also observed increased plasma adrenocorticotropic hormone and corticotropin-releasing factor mRNA in the paraventricular nucleus, known to be instrumental in HPA axis activity, in response to N/OFQ, leading the authors to conclude that N/OFQ mediates HPA axis activation^[@CR52]^. Limbic system involvement is also evident, as acute restraint stress increased N/OFQ expression in hippocampal subfields and was associated with concentration of glucocorticoids^[@CR53]^. However, HPA axis activity effects appear to occur through additive actions in multiple brain regions, since ICV injection of N/OFQ also resulted in elevated corticosterone levels^[@CR54]^.Table 3NOPr in stress modulationExperimentAnimalFindingsReferenceN/OFQ knockoutMice↑CORTJenck et al.^[@CR55]^N/OFQ knockout/N/OFQ ICVMice↓ Adaptability to repeated stress/↑ adaptability to stress (with N/OFQ ICV)Koster et al.^[@CR56]^; Griebel et al.^[@CR125]^N/OFQMale Sprague-Dawley rats↑CORT, ACTH in unstressed rats and mildly stressed ratsDevine et al.^[@CR50]^N/OFQ ICVMice↓CORTLe Cudennec et al.^[@CR57]^N/OFQ ICVMale long Evans rats↑ CORTGreen et al.^[@CR54]^N/OFQ subcutaneously and injectionsMice↑CORT (only injections do this---thus reconsider methodology and environmental stressors)Prince-Zullig et al.^[@CR62]^N/OFQ ICVMale Sprague-Dawley rats↑plasma ACTH, CRF mRNA in PVNLeggett et al.^[@CR52]^Acute restraint stress+NOPr antagonismMale Sprague-Dawley rats↑ Activation of HPA axis in nadir phase (not in peak phase)Leggett et al.^[@CR126]^LPS+NOPr antagonismMale Sprague-Dawley rats↓ Activation of HPA axisLeggett et al.^[@CR127]^Social defeat stressMale/female Long Evans rats↑ NOPr mRNA in PVNGreen and Devine^[@CR58]^JTC-801+acute restraintMale Sprague-Dawley rats↑ HPA axis response/↓ NOPr gene expression in hypothalamusDelaney et al.^[@CR128]^Acute restraint stressMale Sprague-Dawley rats↓N/OFQ in basal forebrainDevine et al.^[@CR51]^Social stressMice↑ NOPr mRNA, N/OFQ precursor mRNAReiss et al.^[@CR59]^Acute restraint stressMale Wistar rats↑ N/OFQ in HPC subfieldsNativio et al.^[@CR53]^Acute restraint stressMale Wistar rats↑ N/OFQCiccocioppo et al.^[@CR60]^Social defeat stressMale Wistar rats↑ N/OFQ mRNA in NAcc shellDer-Avakian et al.^[@CR61]^*LPS* lipopolysaccharide (physiological stress), *JTC-801* NOPr antagonist with partial agonist properties, *CORT* corticosterone, *ACTH* adrenocorticotropic hormone, *CRF* corticotropin-releasing factor, *PVN* paraventricular nucleus, *HPA* *axis* hypothalamic--pituitary-adrenal axis, *HPC* hippocampus, *NAcc* nucleus accumbens

Genetic knockout of N/OFQ reduced the adaptability of mice to stress, but resulted in an elevated level of plasma corticosterone, demonstrating that the effect of NOPr on the HPA axis may be inhibitory^[@CR55]^. In another study, N/OFQ knockout mice had impaired adaptation to stress, furthering the theory of NOPr involvement in stress adaptability^[@CR56]^. In this study, exposure to repeated stress by way of a forced-swim test failed to produce adaptability in knockout mice, while an increase in anxiety-like behavior was also noted.

Similarly, Le Cudennec et al. showed N/OFQ to decrease corticosterone levels following stress, indicating anti-stress effects of this neurotransmitter and also an inhibitory effect on the HPA axis^[@CR57]^. These differential findings may arise due to species differences, but may also indicate a dynamic role of NOPr modulation of stress reactivity. Social stress (in different forms) increased N/OFQ and NOPr mRNA in the hippocampus, central amygdala, paraventricular nucleus, and in the nucleus accumbens shell^[@CR58]--[@CR61]^.

Differential results do exist, such as those obtained by Prince-Zullig et al.^[@CR62]^ They reported no difference in basal corticosterone levels between N/OFQ knockout mice and wild-type controls, in direct contrast with those of Koster et al.^[@CR56]^ Additionally, they found N/OFQ administration to have no significant impact on corticosterone levels compared to saline-injected controls, contradicting prior evidence and suggesting a role of environmental stressors or the injection procedure itself in producing these elevated responses. Such effects have also been noted previously (see review: Gavioli et al.^[@CR63]^). These differences may arise from the NOPr system's significant involvement in pain, as one study showed a lack of HPA activation in a neuropathic pain model, thus implicating pain in HPA axis activation^[@CR64]^.

We also note that the NOPr system plays a role in the production of cytokines, with several studies demonstrating its peripheral impact on the immune system (see review: Bodera et al.)^[@CR65]--[@CR67]^. This could also account for HPA axis activation. Nonetheless, the accumulation of this evidence thus far aligns itself with the findings of a dysregulated HPA axis in schizophrenia patients^[@CR6]^, given the apparently modulatory role of NOPr on the HPA axis.

Involvement of the NOPr system in cognition {#Sec7}
-------------------------------------------

Cognitive deficits are a prevalent finding in the schizophrenia population, with deficits in working memory being commonplace^[@CR2]^. The NOPr system has been shown to play a role in cognition, based on evidence from preclinical studies. These findings are summarized in Table [4](#Tab4){ref-type="table"}. Initial evidence demonstrated spatial learning deficits after N/OFQ injection into the rat hippocampus, and blocking of these effects by NOPr antagonism^[@CR68]--[@CR70]^. Higgins et al. also observed improved performance in N/OFQ knockout rats, with dose-dependent reductions in swim speed, demonstrating effects on locomotion^[@CR70]^. Similarly, Sandin et al. demonstrated a dose-dependent biphasic effect of N/OFQ on spatial learning, with low doses improving learning and higher doses impairing it^[@CR71]^. In contrast, Kuzmin et al. replicated these findings in mice with ICV administration of N/OFQ and observed no biphasic effect, suggesting potential species differences^[@CR72]^. Questions regarding the mechanism of NOPr signaling effects on cognition do exist, as Koster et al. demonstrated N/OFQ knockout mice to have no difference in spatial learning compared to controls^[@CR56]^.Table 4NOPr in cognitionExperimentAnimalFindingsReferenceN/OFQ intrahippocampallyMale Sprague-Dawley rats↓ Spatial learning in MWMSandin et al.^[@CR68]^; Redrobe et al.^[@CR69]^N/OFQ knockoutMiceNo effect on spatial learningKoster et al.^[@CR56]^Retro-nociceptin methylesterMice↑ Learning abilityJinsmaa et al.^[@CR129]^N/OFQMice↓ Latent learningNoda^[@CR130]^NOPr knockoutMice↑ Spatial learning (↓ DA in frontal cortex in knockout mice)Mamiya et al.^[@CR131]^Ro64-6198/N/OFQ knockoutMice/Lister hooded rats↓ Spatial learning in MWM/ ↓ LTPHiggins et al.^[@CR70]^N/OFQ intrahippocampallyMale Sprague-Dawley rats↓ Spatial learning at high doses/↑ spatial learning at low doses (biphasic effect)Sandin et al.^[@CR71]^N/OFQ ICV/ Prepro N/OFQ knockoutMice↓ Spatial learning in MWM/ ↑ learning in knockout miceKuzmin et al.^[@CR72]^N/OFQ ICVMice↓ Working memory in passive avoidance taskHiramatsu and Inoue^[@CR74]^; Liu et al.^[@CR132]^NOPr knockoutMice↑ Learning and memory (with novel KUROBOX apparatus)Nagai et al.^[@CR133]^NOPr knockoutMice↑ Working memory in passive avoidance taskMamiya et al.^[@CR73]^NOPr knockoutMice↑ Learning ability and memoryNoda et al.^[@CR134]^NOPr knockoutMice↑ Working/spatial memory in MWM, passive avoidance task/ ↑ LTPManabe et al.^[@CR76]^; Taverna et al.^[@CR135]^N/OFQ (tetanic stimulation)Mice↓ LTP (hippocampal CA1 region)Bongsebandhu-phubakdi and Manabe^[@CR78]^N/OFQMale Sprague-Dawley rats / Mice↓ LTP in HPC/↓NMDAr-mediated EPSC / ↓LTDYu et al.^[@CR82]^; Yu and Xie^[@CR75]^; Wei and Xie^[@CR77]^N/OFQ intrahippocampallyMice↓ Memory impairmentMiwa et al.^[@CR136]^Ro64-6198/mecamylamineMice↓ Recognition memory in object recognition taskReiss et al.^[@CR79]^N/OFQ ICV or Ro64-6198/MK-801Mice↓ Recognition memory in object recognition task /↓ long-term memory formation (administered together)Goeldner et al.^[@CR80]^N/OFQ ICVMale Wistar rats↓ ACh release in striatumItoh et al.^[@CR83]^N/OFQRats---in vitro↓ ACh efflux in cortical and hippocampal slicesCavallini et al.^[@CR84]^NOPr knockoutMice↑ ACh in hippocampus (and ↑ hippocampal theta rhythm)Uezu et al.^[@CR85]^N/OFQ ICVMale Sprague-Dawley rats↓ Mecamylamine impairment at low doses / memory impairment at high dosesHiramatsu et al.^[@CR86]^*MWM* Morris water maze, *LTP* long-term potentiation, *LTD* long-term depression, *Retro-nociceptin methylester* NOPr antagonist, *ACh* acetylcholine, *Mecamylamine* nicotinic receptor antagonist

Moreover, working memory impairments have been noted via insufficiencies in passive avoidance in animals following NOPr activation through administration of agonists or N/OFQ^[@CR70],[@CR73],[@CR74]^. NOPr activation impaired long-term memory formation as measured through recognition memory. The mechanism for this is potentially via the suppression of glutamatergic function at the NMDA receptor^[@CR75]--[@CR78]^. Reiss et al. demonstrated selective impairment of recognition memory in mice following co-administration of a NOPr agonist and NMDA receptor antagonist, further demonstrating NOPr system modulation of memory formation via glutamatergic receptors^[@CR79]^. These findings have since found additional support with deficits in recognition memory and fear learning in mice following increases in NOPr activity mediated via suppression of glutamate transmission^[@CR80],[@CR81]^. Furthermore, a negative impact of NOPr signaling on long-term potentiation (LTP) in the hippocampus has also been observed, as NOPr-deficient mice had improved LTP, gauged through NOPr and N/OFQ gene expression in the hippocampus^[@CR70],[@CR75],[@CR76],[@CR82]^.

Acetylcholine (ACh) signaling is posited to play a role in the cognitive deficits observed in schizophrenia^[@CR7]^, and the NOPr system is also implicated with this neurotransmitter. Initial in vivo evidence showed N/OFQ to decrease ACh release in the striatum in rats^[@CR83]^. This was later corroborated with similar evidence in cortical and hippocampal regions, thus further demonstrating effects of the NOPr system on cognition^[@CR84]^. Uezu et al. reported specific findings in the hippocampus, with knockout mice having greater amounts of ACh, leading the authors to speculate an impact of NOPr signaling on memory function^[@CR85]^. Findings by Hiramatsu et al. indicate a dose-dependent effect of N/OFQ on ACh signaling, as they found high doses to decrease it, while lower doses countered antagonist-induced ACh signaling decrease^[@CR86]^. Additional research is necessary in order to further elucidate the mechanisms by which these effects occur.

Collectively, these results confirm an involvement of NOPr signaling on cognition including working memory deficits, spatial working memory deficits, and impairments in LTP. Dopaminergic dysfunction, glutamatergic hypofunction, and effects on cholinergic transmission have been outlined as mechanisms that may underlie these deficits^[@CR87]--[@CR89]^, and hence, aberrant NOPr signaling may play a crucial role in the cognitive deficits of schizophrenia.

Involvement of the NOPr system in reward modulation {#Sec8}
---------------------------------------------------

Deficits in reward processing and motivation are a common finding in schizophrenia^[@CR3]^. Through investigations into the rewarding properties of drugs of abuse, the NOPr system could be involved in reward modulation, particularly since a moderate-to-high concentration of NOPr in regions associated with reward is observed, including the ventral tegmental area, medial prefrontal cortex, amygdala, and the bed nucleus of the stria terminalis^[@CR11]^. The findings are summarized in Table [5](#Tab5){ref-type="table"}. Conditioned place preference (CPP) is a valid method for the study of motivational effects and reward in different paradigms^[@CR90]^. Thus, studies with NOPr signaling in CPP can aid understanding of the role of the NOPr system in reward. Treatment with N/OFQ resulted in an inhibition of reward salience, as measured via CPP, and these findings were replicated with multiple drugs of abuse, including morphine, cocaine, and amphetamines^[@CR91]--[@CR95]^. Similarly, NOPr antagonism or knockout results in an increase in CPP with drugs of abuse^[@CR96]--[@CR98]^. However, the literature is still inconsistent as an increase in CPP has also been observed with NOPr agonism^[@CR98],[@CR99]^. Endogenous N/OFQ does not have any reinforcing effects, indicating that it in itself does not have any effects on CPP^[@CR98]^. Generally, activation of the NOPr system could be involved in negative reinforcement, as agonism has been shown to decrease self-administration of ethanol^[@CR100]^.Table 5NOPr in reward modulationExperimentAnimalFindingsReferenceRo65-6570/N/OFQMale Wistar rats↑ CPP with cocaine/↓ CPP with cocaineKotlinska et al.^[@CR99]^NOPr knockoutMice↑ CPP with cocaineMarquez et al.^[@CR96]^N/OFQ ICVMale Sprague-Dawley rats↓ Cocaine-induced DA release in NAccVazquez-Derose et al.^[@CR92]^Ro65-6570/J-113397Male Sprague-Dawley rats↑ CPP/↓ CPP with antagonist (with opioids)Rutten et al.^[@CR98]^N/OFQ ICVMale Wistar rats/male Sprague-Dawley rats↓ CPP with morphine/↓ sensitization to morphine (using agonists)Ciccocioppo et al.^[@CR93]^; Murphy et al.^[@CR137]^; Kotlinska et al.^[@CR138]^J-113397Male Sprague-Dawley rats↑ CPP with morphineRutten et al.^[@CR91]^N/OFQ ICVMice↓ CPP with morphine and cocaineSakoori and Murphy^[@CR94]^Ro64-6198Male Wistar rats↓ Ethanol self-administrationKuzmin et al.^[@CR100]^N/OFQ knockoutMice↑ CPP with methamphetamine and ethanolSakoori and Murphy^[@CR97]^N/OFQ ICVMale Sprague-Dawley rats↓ CPP with methamphetamineZhao et al.^[@CR139]^N/OFQ ICVMale Wistar rats↓ CPP with amphetamineKotlinska et al.^[@CR95]^NOPr knockoutRats (Wistar controls)↓ Self-administration of cocaine, heroin, ethanol/no difference on saccharin self-administration compared to controlsKallupi et al.^[@CR102]^CebranopadolMale Wistar rats↓ Self-administration of cocaine/no effect on sweetened condensed milk self-administrationde Guglielmo et al.^[@CR103]^N/OFQ ICVMice↑ Licking for sweet solutionsMendez et al.^[@CR101]^*Ro65-6570* NOPr agonist (w/out motivational properties---unlike Ro64-6198), *CPP* conditioned place preference, *Cebranopadol* NOPr full agonist (also full agonist of mu, partial agonist of kappa and delta opioid receptors)

This discrepancy is highlighted by more recent findings regarding the NOPr system in reward and motivation. ICV administration of N/OFQ increased bouts of licking for sucrose (a sweet solution) in mice, which led to the suggestion that activation of this system increases the motivation associated with appetite^[@CR101]^. Conversely, NOPr knockout rats in another study did not differ from wild-type controls in their preference for saccharin, although these rats did have a significantly reduced proclivity for self-administration of cocaine, heroin, and alcohol^[@CR102]^. A similar finding was observed in a comparison between cocaine and sweetened condensed milk^[@CR103]^. These results suggest a role for the NOPr system in drug reward specifically, but are also inconsistent with previous findings of a role in motivation in general. These differences could be a result of inherent species differences as well as a difference in methodology (i.e., licking microstructure analysis versus fixed-ratio self-administration).

Another recent study demonstrated negative correlations between reward learning and N/OFQ peptide mRNA levels in the cingulate gyrus and with NOPr mRNA levels in the ventral tegmental area^[@CR61]^. Overall, the results align with the reward system disruptions noted in schizophrenia, in which the existence of deficits is well supported by the literature^[@CR3]^. The NOPr system may thus play a role in these deficits, further potentiating its involvement in the pathophysiology of schizophrenia.

Conclusion and future directions {#Sec9}
--------------------------------

In summary, the literature indicates a role of the NOPr system in dopamine and glutamate regulation, with NOPr activation generally decreasing dopamine and glutamate transmission, although this requires further elucidation. Activation of NOPr is also associated with HPA axis regulation, implicating a role for it in the modulation of stress. Cognition is generally negatively impacted with NOPr activation. While reports of the system's impact on the reward system are mixed, they nonetheless point to the existence of an effect. Indeed, the NOPr system has potential in other psychiatric illnesses, such as depression, in which antagonism is demonstrated to have promising effectiveness^[@CR104]^.

Due to the multi-faceted effects of the NOPr system in the brain, how exactly it may be altered in psychosis remains to be elucidated. This preclinical and in vitro evidence presented in conjunction with the well-replicated findings in schizophrenia clearly implicate a plausible contribution of the NOPr system in the pathophysiology of schizophrenia^[@CR89],[@CR105]^. The literature we have presented in this review indicates the paucity in this field and thus highlights the need for further research. The development and validation of the novel PET tracer \[^11^C\]NOP-1A now makes this possible to investigate in clinical populations^[@CR13],[@CR106]^.

In conclusion, we present here a novel approach to a complex neuropsychiatric illness and demonstrate that the literature suggests a potential role of the NOPr system in schizophrenia, with ramifications in the development of better treatment and interventions, and possibly even prevention.
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